Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis.

Br J Haematol · 2026 · PMC12916197 · PMID 41344892

Europe PMC DOI

hedged sentences

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

showed a trendp = 0.13not close (p > 0.1)

Among transplanted patients, CPX showed a trend towards higher 1‐year OS (77.8% vs. 67.7%, p = 0.13).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Although differences did not reach statistical significance, higher IFI rates, fewer transplants in CR++ and earlier relapse may have mitigated FLAG‐IDA's apparent CR advantage.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.